CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity

BackgroundWhile chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for certain hematologic malignancies, therapeutic resistance and disease relapse highlight the critical need to improve the durability of clinical responses. The limited in vivo persistence and ant...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer Vol. 13; no. 11; p. e012243
Main Authors:	Wu, Jia, Cheng, Jiali, Zhu, Li, Gao, Qiang, Lin, Haolong, Zeng, Yuhao, Li, Yong, Li, Weini, An, Ning, Huang, Liang, Xiao, Min, Li, Dengju, Mu, Wei
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd 29.11.2025 BMJ Publishing Group LTD BMJ Publishing Group
Subjects:	Ablation Adoptive cell therapy - ACT Animals Antibodies Antigens CD5 Antigens - genetics CD5 Antigens - metabolism Cell growth Cell Line, Tumor Clinical outcomes Clinical trials Cloning Cytotoxicity Cytotoxicity, Immunologic Flow cytometry Genes Humans Immune cell therapies and immune cell engineering Immune modulatory Immunotherapy Immunotherapy, Adoptive - methods Lymphocytes Lymphoma Mice Proteins T cell T-Lymphocytes - immunology T-Lymphocytes - metabolism Tumor necrosis factor-TNF Xenograft Model Antitumor Assays China Immune modulatory Adoptive cell therapy - ACT Immunotherapy T cell
ISSN:	2051-1426, 2051-1426
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!